Annual CFO
-$31.41 M
+$144.76 M+82.17%
31 December 2023
Summary:
TG Therapeutics annual cash flow from operations is currently -$31.41 million, with the most recent change of +$144.76 million (+82.17%) on 31 December 2023. During the last 3 years, it has risen by +$183.09 million (+85.36%). TGTX annual CFO is now -36173.67% below its all-time high of -$86.60 thousand, reached on 31 December 2011.TGTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$12.21 M
-$17.74 M-320.47%
30 September 2024
Summary:
TG Therapeutics quarterly cash flow from operations is currently -$12.21 million, with the most recent change of -$17.74 million (-320.47%) on 30 September 2024. Over the past year, it has dropped by -$95.91 million (-114.58%). TGTX quarterly CFO is now -114.58% below its all-time high of $83.70 million, reached on 30 September 2023.TGTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$28.09 M
-$95.91 M-141.41%
30 September 2024
Summary:
TG Therapeutics TTM cash flow from operations is currently -$28.09 million, with the most recent change of -$95.91 million (-141.41%) on 30 September 2024. Over the past year, it has increased by +$13.99 million (+33.24%). TGTX TTM CFO is now -141.41% below its all-time high of $67.82 million, reached on 30 June 2024.TGTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TGTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +82.2% | -114.6% | +33.2% |
| 3 y3 years | +85.4% | +81.8% | +89.2% |
| 5 y5 years | +75.6% | +63.2% | +79.4% |
TGTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +89.4% | -114.6% | +86.0% | -141.4% | +90.5% |
| 5 y | 5 years | at high | +89.4% | -114.6% | +86.0% | -141.4% | +90.5% |
| alltime | all time | <-9999.0% | +89.4% | -114.6% | +86.0% | -141.4% | +90.5% |
TG Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$12.21 M(-320.5%) | -$28.09 M(-141.4%) |
| June 2024 | - | $5.54 M(-167.5%) | $67.82 M(+234.4%) |
| Mar 2024 | - | -$8.21 M(-37.9%) | $20.28 M(-164.6%) |
| Dec 2023 | -$31.41 M(-82.2%) | -$13.21 M(-115.8%) | -$31.41 M(-25.3%) |
| Sept 2023 | - | $83.70 M(-299.3%) | -$42.07 M(-73.7%) |
| June 2023 | - | -$42.01 M(-29.9%) | -$160.27 M(-4.2%) |
| Mar 2023 | - | -$59.90 M(+151.0%) | -$167.38 M(-5.0%) |
| Dec 2022 | -$176.17 M(-40.4%) | -$23.87 M(-30.8%) | -$176.17 M(-26.4%) |
| Sept 2022 | - | -$34.49 M(-29.8%) | -$239.21 M(-12.0%) |
| June 2022 | - | -$49.12 M(-28.5%) | -$271.92 M(-3.9%) |
| Mar 2022 | - | -$68.69 M(-21.0%) | -$282.97 M(-4.3%) |
| Dec 2021 | -$295.63 M(+37.8%) | -$86.91 M(+29.3%) | -$295.63 M(+13.4%) |
| Sept 2021 | - | -$67.20 M(+11.7%) | -$260.75 M(+4.3%) |
| June 2021 | - | -$60.17 M(-26.0%) | -$250.08 M(+7.0%) |
| Mar 2021 | - | -$81.36 M(+56.4%) | -$233.75 M(+9.0%) |
| Dec 2020 | -$214.51 M(+61.5%) | -$52.03 M(-8.0%) | -$214.51 M(+11.2%) |
| Sept 2020 | - | -$56.53 M(+29.0%) | -$192.87 M(+13.8%) |
| June 2020 | - | -$43.83 M(-29.4%) | -$169.54 M(+4.9%) |
| Mar 2020 | - | -$62.12 M(+104.4%) | -$161.57 M(+21.7%) |
| Dec 2019 | -$132.81 M(+3.0%) | -$30.39 M(-8.5%) | -$132.81 M(-2.4%) |
| Sept 2019 | - | -$33.20 M(-7.4%) | -$136.10 M(+0.1%) |
| June 2019 | - | -$35.86 M(+7.5%) | -$135.91 M(+1.2%) |
| Mar 2019 | - | -$33.35 M(-1.0%) | -$134.23 M(+4.1%) |
| Dec 2018 | -$128.93 M(+37.5%) | -$33.69 M(+2.1%) | -$128.93 M(+10.1%) |
| Sept 2018 | - | -$33.01 M(-3.4%) | -$117.09 M(+9.6%) |
| June 2018 | - | -$34.18 M(+21.9%) | -$106.86 M(+7.4%) |
| Mar 2018 | - | -$28.04 M(+28.3%) | -$99.50 M(+6.1%) |
| Dec 2017 | -$93.76 M(+52.2%) | -$21.86 M(-4.0%) | -$93.76 M(+5.4%) |
| Sept 2017 | - | -$22.77 M(-15.1%) | -$88.93 M(+9.5%) |
| June 2017 | - | -$26.83 M(+20.3%) | -$81.19 M(+20.8%) |
| Mar 2017 | - | -$22.30 M(+31.0%) | -$67.21 M(+9.1%) |
| Dec 2016 | -$61.59 M(+37.8%) | -$17.02 M(+13.2%) | -$61.59 M(+7.2%) |
| Sept 2016 | - | -$15.04 M(+17.1%) | -$57.47 M(+8.3%) |
| June 2016 | - | -$12.85 M(-22.9%) | -$53.08 M(+1.1%) |
| Mar 2016 | - | -$16.67 M(+29.2%) | -$52.48 M(+17.4%) |
| Dec 2015 | -$44.69 M(+27.5%) | -$12.90 M(+21.0%) | -$44.69 M(-4.7%) |
| Sept 2015 | - | -$10.66 M(-13.0%) | -$46.90 M(+5.9%) |
| June 2015 | - | -$12.25 M(+37.9%) | -$44.29 M(+24.4%) |
| Mar 2015 | - | -$8.88 M(-41.2%) | -$35.61 M(+1.6%) |
| Dec 2014 | -$35.06 M(+226.5%) | -$15.11 M(+87.6%) | -$35.06 M(+41.5%) |
| Sept 2014 | - | -$8.05 M(+125.3%) | -$24.78 M(+38.6%) |
| June 2014 | - | -$3.57 M(-57.1%) | -$17.88 M(+6.0%) |
| Mar 2014 | - | -$8.33 M(+72.7%) | -$16.86 M(+57.0%) |
| Dec 2013 | -$10.74 M(+107.0%) | -$4.82 M(+318.0%) | -$10.74 M(+59.1%) |
| Sept 2013 | - | -$1.15 M(-54.9%) | -$6.75 M(-21.4%) |
| June 2013 | - | -$2.56 M(+16.0%) | -$8.59 M(+31.5%) |
| Mar 2013 | - | -$2.20 M(+164.6%) | -$6.53 M(+25.9%) |
| Dec 2012 | -$5.19 M(+5890.8%) | -$833.30 K(-72.2%) | -$5.19 M(+17.6%) |
| Sept 2012 | - | -$2.99 M(+498.9%) | -$4.41 M(+204.6%) |
| June 2012 | - | -$499.80 K(-42.0%) | -$1.45 M(<-9900.0%) |
| Mar 2012 | - | -$861.60 K(+1425.0%) | $0.00(-100.0%) |
| Dec 2011 | -$86.60 K(-95.6%) | -$56.50 K(+87.7%) | -$86.60 K(-84.9%) |
| Sept 2011 | - | -$30.10 K(-103.2%) | -$571.80 K(-40.1%) |
| June 2011 | - | $948.20 K(-200.0%) | -$954.40 K(-58.7%) |
| Mar 2011 | - | -$948.20 K(+75.0%) | -$2.31 M(+17.4%) |
| Dec 2010 | -$1.97 M | -$541.70 K(+31.3%) | -$1.97 M(+12.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | -$412.70 K(+0.5%) | -$1.76 M(+18.3%) |
| June 2010 | - | -$410.80 K(-32.1%) | -$1.48 M(+47.1%) |
| Mar 2010 | - | -$604.80 K(+84.9%) | -$1.01 M(-3.9%) |
| Dec 2009 | -$1.05 M(-76.4%) | -$327.10 K(+132.2%) | -$1.05 M(-36.1%) |
| Sept 2009 | - | -$140.90 K(-319.8%) | -$1.64 M(-22.6%) |
| June 2009 | - | $64.10 K(-109.9%) | -$2.12 M(-41.5%) |
| Mar 2009 | - | -$645.80 K(-29.8%) | -$3.63 M(-18.4%) |
| Dec 2008 | -$4.44 M(-56.6%) | -$919.80 K(+48.3%) | -$4.44 M(-9.4%) |
| Sept 2008 | - | -$620.30 K(-57.0%) | -$4.91 M(-30.3%) |
| June 2008 | - | -$1.44 M(-1.3%) | -$7.04 M(-25.9%) |
| Mar 2008 | - | -$1.46 M(+5.7%) | -$9.51 M(-7.0%) |
| Dec 2007 | -$10.23 M(+32.0%) | -$1.38 M(-49.8%) | -$10.23 M(+0.1%) |
| Sept 2007 | - | -$2.76 M(-29.5%) | -$10.21 M(+6.5%) |
| June 2007 | - | -$3.91 M(+79.3%) | -$9.59 M(+17.6%) |
| Mar 2007 | - | -$2.18 M(+59.4%) | -$8.16 M(+5.2%) |
| Dec 2006 | -$7.75 M(+24.1%) | -$1.37 M(-35.8%) | -$7.75 M(-8.2%) |
| Sept 2006 | - | -$2.13 M(-14.0%) | -$8.44 M(+9.1%) |
| June 2006 | - | -$2.48 M(+39.6%) | -$7.74 M(+14.8%) |
| Mar 2006 | - | -$1.78 M(-13.9%) | -$6.74 M(+8.0%) |
| Dec 2005 | -$6.24 M(+9.7%) | -$2.06 M(+44.7%) | -$6.24 M(+1.1%) |
| Sept 2005 | - | -$1.43 M(-3.6%) | -$6.18 M(-0.3%) |
| June 2005 | - | -$1.48 M(+15.7%) | -$6.19 M(+8.9%) |
| Mar 2005 | - | -$1.28 M(-35.9%) | -$5.69 M(-0.0%) |
| Dec 2004 | -$5.69 M(+64.9%) | -$2.00 M(+38.4%) | -$5.69 M(+5.2%) |
| Sept 2004 | - | -$1.44 M(+48.2%) | -$5.41 M(+20.5%) |
| June 2004 | - | -$973.00 K(-24.0%) | -$4.49 M(+7.3%) |
| Mar 2004 | - | -$1.28 M(-25.3%) | -$4.19 M(+21.3%) |
| Dec 2003 | -$3.45 M(+350.8%) | -$1.72 M(+227.8%) | -$3.45 M(+160.3%) |
| Sept 2003 | - | -$523.20 K(-21.8%) | -$1.33 M(-10.1%) |
| June 2003 | - | -$668.70 K(+22.9%) | -$1.47 M(+113.6%) |
| Mar 2003 | - | -$544.30 K(-232.7%) | -$690.30 K(-9.8%) |
| Dec 2002 | -$765.70 K(-82.9%) | $410.10 K(-161.0%) | -$765.70 K(-61.0%) |
| Sept 2002 | - | -$671.80 K(-680.6%) | -$1.96 M(+4.7%) |
| June 2002 | - | $115.70 K(-118.7%) | -$1.88 M(-30.9%) |
| Mar 2002 | - | -$619.70 K(-21.4%) | -$2.72 M(-39.3%) |
| Dec 2001 | -$4.47 M(+288.1%) | -$788.80 K(+35.3%) | -$4.47 M(+105.5%) |
| Sept 2001 | - | -$583.00 K(-19.6%) | -$2.18 M(-1.1%) |
| June 2001 | - | -$724.80 K(-69.5%) | -$2.20 M(-29.2%) |
| Mar 2001 | - | -$2.38 M(-257.6%) | -$3.11 M(+169.5%) |
| Dec 2000 | -$1.15 M(-49.9%) | $1.51 M(-348.9%) | -$1.15 M(-59.7%) |
| Sept 2000 | - | -$606.20 K(-62.9%) | -$2.86 M(+7.8%) |
| June 2000 | - | -$1.63 M(+285.2%) | -$2.66 M(+38.0%) |
| Mar 2000 | - | -$423.60 K(+111.8%) | -$1.92 M(-16.4%) |
| Dec 1999 | -$2.30 M(-11.5%) | -$200.00 K(-50.0%) | -$2.30 M(-30.3%) |
| Sept 1999 | - | -$400.00 K(-55.6%) | -$3.30 M(-21.4%) |
| June 1999 | - | -$900.00 K(+12.5%) | -$4.20 M(+110.0%) |
| Mar 1999 | - | -$800.00 K(-33.3%) | -$2.00 M(-23.1%) |
| Dec 1998 | -$2.60 M(-36.6%) | -$1.20 M(-7.7%) | -$2.60 M(0.0%) |
| Sept 1998 | - | -$1.30 M(-200.0%) | -$2.60 M(+8.3%) |
| June 1998 | - | $1.30 M(-192.9%) | -$2.40 M(-48.9%) |
| Mar 1998 | - | -$1.40 M(+16.7%) | -$4.70 M(+14.6%) |
| Dec 1997 | -$4.10 M(+2.5%) | -$1.20 M(+9.1%) | -$4.10 M(+41.4%) |
| Sept 1997 | - | -$1.10 M(+10.0%) | -$2.90 M(+61.1%) |
| June 1997 | - | -$1.00 M(+25.0%) | -$1.80 M(+125.0%) |
| Mar 1997 | - | -$800.00 K | -$800.00 K |
| Dec 1996 | -$4.00 M | - | - |
FAQ
- What is TG Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for TG Therapeutics?
- What is TG Therapeutics annual CFO year-on-year change?
- What is TG Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for TG Therapeutics?
- What is TG Therapeutics quarterly CFO year-on-year change?
- What is TG Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for TG Therapeutics?
- What is TG Therapeutics TTM CFO year-on-year change?
What is TG Therapeutics annual cash flow from operations?
The current annual CFO of TGTX is -$31.41 M
What is the all time high annual CFO for TG Therapeutics?
TG Therapeutics all-time high annual cash flow from operations is -$86.60 K
What is TG Therapeutics annual CFO year-on-year change?
Over the past year, TGTX annual cash flow from operations has changed by +$144.76 M (+82.17%)
What is TG Therapeutics quarterly cash flow from operations?
The current quarterly CFO of TGTX is -$12.21 M
What is the all time high quarterly CFO for TG Therapeutics?
TG Therapeutics all-time high quarterly cash flow from operations is $83.70 M
What is TG Therapeutics quarterly CFO year-on-year change?
Over the past year, TGTX quarterly cash flow from operations has changed by -$95.91 M (-114.58%)
What is TG Therapeutics TTM cash flow from operations?
The current TTM CFO of TGTX is -$28.09 M
What is the all time high TTM CFO for TG Therapeutics?
TG Therapeutics all-time high TTM cash flow from operations is $67.82 M
What is TG Therapeutics TTM CFO year-on-year change?
Over the past year, TGTX TTM cash flow from operations has changed by +$13.99 M (+33.24%)